Maki Imakura is a Registered USPTO Patent Attorney who is excited to work with entrepreneurs and business working on cutting-edge technology. She received a B.S. in Cellular & Molecular Biology with a minor in Chemistry from the University of Washington. Maki received her J.D. from the Seattle University School of Law. Maki draws on her technical background in life sciences research and experiences with drug discovery involving large data sets and collaboration to provide a unique perspective for clients on their technology and intellectual property needs.
During her scientific career, Maki worked in the fields of cancer research and drug discovery. Maki conducted research in labs at the University of Washington, the Fred Hutchinson Cancer Research Institute, and Rosetta Inpharmatics, a wholly owned subsidiary of Merck & Co., Inc. She worked on analyzing mutants of the HIV-1 vpr gene for the gene’s involvement in nuclear import and export. Maki’s industry experience focused on the area of oncology and developing expertise in automation and high-throughput techniques, leading to developing and running Merck’s first genome-scale siRNA screen.